MediciNova Inc. (MNOV)

Overview

MediciNova, Inc. is a forward-looking biopharmaceutical company committed to the discovery and development of unique small molecule therapeutics intended to treat serious diseases for which there is a significant unmet medical need. With a steadfast focus on neurological conditions and other critical disorders, the company is pioneering efforts to bring innovative treatments to the U.S. market. Established in the year 2000, MediciNova maintains its headquarters in La Jolla, California, symbolizing its integral role within the thriving biotech industry of the United States. Through strategic license agreements with partners like Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd., MediciNova is enhancing its product pipeline and accelerating the path to treatment advancements and commercial success.

Products and Services

• MN-166 (ibudilast)

  At the forefront of MediciNova's innovative pipeline is MN-166, an orally administered anti-inflammatory and neuroprotective agent. This promising therapeutic is under development for a broad spectrum of neurological and other disorders, including primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, and substance dependence and addiction. Moreover, MN-166 is being explored for its potential in preventing acute respiratory distress syndrome and combating the lingering effects of long COVID.

• MN-221 (bedoradrine)

  This selective beta-2-adrenergic receptor agonist targets the acute exacerbations of asthma. MN-221 represents MediciNova's commitment to addressing respiratory conditions with novel therapeutic approaches, aiming to provide relief for asthma sufferers during severe flare-ups where traditional therapies may fall short.

• MN-001 (tipelukast)

  A versatile orally bioavailable molecule, MN-001 has potential applications across a variety of fibrotic diseases. The drug is under investigation for conditions such as nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis, showcasing MediciNova's dedication to tackling challenging fibrotic conditions with innovative solutions.

• MN-029 (denibulin)

  As a tubulin binding agent, MN-029 is being explored for its effectiveness in treating solid tumor cancers. This product illustrates MediciNova’s entry into oncology, with an aim to develop more targeted and potentially less toxic cancer therapies. Through its action mechanism, MN-029 could offer a new hope for patients battling these life-threatening conditions.